James is the Chief Executive Officer of Renalytix AI an AIM listed Kidney Diagnostic company. James has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His skills include equity and debt capital formation, strategic development and partnerships, executive team structuring, regulatory issues and marketing. James was most recently chief executive officer of Exosome Diagnostics, a venture backed personalised medicine company developing non-invasive liquid biopsy diagnostics in cancer. James is also a managing partner of Renwick Capital, LLC (“Renwick”), a management consulting firm specialising in assisting emerging healthcare technology companies with strategic planning and business execution and a co-founder of PAIGE.AI, a computational pathology spin-out from the Memorial Sloan Kettering Cancer Center.